JP2018184428A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018184428A5 JP2018184428A5 JP2018131226A JP2018131226A JP2018184428A5 JP 2018184428 A5 JP2018184428 A5 JP 2018184428A5 JP 2018131226 A JP2018131226 A JP 2018131226A JP 2018131226 A JP2018131226 A JP 2018131226A JP 2018184428 A5 JP2018184428 A5 JP 2018184428A5
- Authority
- JP
- Japan
- Prior art keywords
- gdf11
- activity
- level
- seq
- configuration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 48
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 description 48
- 230000000694 effects Effects 0.000 description 47
- 238000000034 method Methods 0.000 description 30
- 239000003112 inhibitor Substances 0.000 description 19
- 108010052946 Activin Receptors Proteins 0.000 description 17
- 102000018918 Activin Receptors Human genes 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 208000007502 anemia Diseases 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 208000005980 beta thalassemia Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000003924 normoblast Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102100021886 Activin receptor type-2A Human genes 0.000 description 1
- 108010057429 activin receptor type II-A Proteins 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000004005 intermediate erythroblast Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261718126P | 2012-10-24 | 2012-10-24 | |
| US61/718,126 | 2012-10-24 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015539750A Division JP6401171B2 (ja) | 2012-10-24 | 2013-10-23 | 貧血の治療に使用するためのバイオマーカー |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020108569A Division JP7146850B2 (ja) | 2012-10-24 | 2020-06-24 | 貧血の治療に使用するためのバイオマーカー |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018184428A JP2018184428A (ja) | 2018-11-22 |
| JP2018184428A5 true JP2018184428A5 (cg-RX-API-DMAC7.html) | 2019-01-10 |
Family
ID=50545462
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015539750A Active JP6401171B2 (ja) | 2012-10-24 | 2013-10-23 | 貧血の治療に使用するためのバイオマーカー |
| JP2018131226A Pending JP2018184428A (ja) | 2012-10-24 | 2018-07-11 | 貧血の治療に使用するためのバイオマーカー |
| JP2020108569A Active JP7146850B2 (ja) | 2012-10-24 | 2020-06-24 | 貧血の治療に使用するためのバイオマーカー |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015539750A Active JP6401171B2 (ja) | 2012-10-24 | 2013-10-23 | 貧血の治療に使用するためのバイオマーカー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020108569A Active JP7146850B2 (ja) | 2012-10-24 | 2020-06-24 | 貧血の治療に使用するためのバイオマーカー |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20150276766A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2912462B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6401171B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN113604550A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2013334659B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2889209C (cg-RX-API-DMAC7.html) |
| ES (2) | ES3031001T3 (cg-RX-API-DMAC7.html) |
| IL (3) | IL267663B (cg-RX-API-DMAC7.html) |
| SA (1) | SA515360337B1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014066486A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105001320A (zh) | 2005-11-23 | 2015-10-28 | 阿塞勒隆制药公司 | Activin-ActRIIa拮抗剂及其促进骨骼生长的应用 |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| CN101835485B (zh) | 2007-02-01 | 2016-10-26 | 阿塞勒隆制药公司 | 活化素-actriia拮抗剂及在治疗或预防乳腺癌中的用途 |
| TW201940502A (zh) | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| JP5574711B2 (ja) | 2007-02-09 | 2014-08-20 | アクセルロン ファーマ， インコーポレイテッド | 癌患者における骨成長を促進するためのアクチビン−ａｃｔｒｉｉａアンタゴニストおよびその使用 |
| EP3243524A1 (en) | 2007-09-18 | 2017-11-15 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| WO2010019261A1 (en) | 2008-08-14 | 2010-02-18 | Acceleron Pharma Inc. | Use of gdf traps to increase red blood cell levels |
| BRPI1010704B1 (pt) | 2009-06-12 | 2021-12-14 | Acceleron Pharma Inc | Polipeptídeo recombinante, proteína de fusão recombinante, preparação farmacêutica e uso da mesma |
| JP6267425B2 (ja) | 2009-11-17 | 2018-01-24 | アクセルロン ファーマ， インコーポレイテッド | 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用 |
| AU2011326586A1 (en) | 2010-11-08 | 2013-05-30 | Acceleron Pharma, Inc. | ActRIIA binding agents and uses thereof |
| NZ707477A (en) | 2012-11-02 | 2019-09-27 | Celgene Corp | Activin-actrii antagonists and uses for treating bone and other disorders |
| BR112016024319B1 (pt) * | 2014-04-18 | 2024-01-23 | Acceleron Pharma Inc | USO DE UMA COMPOSIÇÃO COMPREENDENDO UM ANTAGONISTA DE ActRII PARA A FABRICAÇÃO DE UM MEDICAMENTO PARA TRATAR OU PREVINIR UMA COMPLICAÇÃO DE ANEMIA FALCIFORME |
| AP2017009674A0 (en) | 2014-06-13 | 2017-01-31 | Acceleron Pharma Inc | Methods and compositions for treating ulcers |
| MA41052A (fr) * | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| JP6768651B2 (ja) * | 2014-11-24 | 2020-10-14 | ソマロジック, インコーポレイテッドSomaLogic, Inc. | 増殖分化因子１１と結合するための核酸化合物 |
| JP2018501307A (ja) * | 2014-12-03 | 2018-01-18 | セルジーン コーポレイション | アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用 |
| JP6959487B2 (ja) | 2015-04-22 | 2021-11-02 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | 筋消耗疾患治療用の新規なハイブリッドａｃｔｒｉｉｂリガンド捕集タンパク質 |
| KR102640198B1 (ko) * | 2015-05-13 | 2024-02-23 | 셀진 코포레이션 | Actrii 리간드 트랩을 사용한 베타-탈라세미아의 치료 |
| WO2016187378A1 (en) * | 2015-05-20 | 2016-11-24 | Celgene Corporation | In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps |
| US11123430B2 (en) | 2015-11-04 | 2021-09-21 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| CN105738614B (zh) * | 2016-02-23 | 2017-12-05 | 山东大学 | 一种应用流式细胞仪分析评价小鼠骨髓红细胞生成功能的方法 |
| RS65735B1 (sr) | 2016-07-27 | 2024-08-30 | Acceleron Pharma Inc | Kompozicije za upotrebu u lečenju mijelofibroze |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| CA3177632A1 (en) | 2020-05-15 | 2021-11-18 | Melih ACAR | Methods and compositions for treating anemia using actriib ligand traps and mtor inhibitors |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| DK0776337T3 (da) * | 1994-07-08 | 2005-12-12 | Univ Johns Hopkins Med | Vækstdifferentieringsfaktor-11 |
| US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| CA2302525A1 (en) | 1997-08-29 | 1999-03-04 | Human Genome Sciences, Inc. | Follistatin-3 |
| EP1356075A4 (en) | 2000-10-16 | 2005-04-13 | Compound Therapeutics Inc | PROTEIN EQUIPMENT FOR ANTIBODY MIMETICS AND OTHER TIE PROTEINS |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| TWI329129B (en) * | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
| ATE472609T1 (de) | 2001-04-26 | 2010-07-15 | Amgen Mountain View Inc | Kombinatorische bibliotheken von monomerdomänen |
| PL374966A1 (en) * | 2002-02-21 | 2005-11-14 | Wyeth | Follistatin domain containing proteins |
| US20070135336A1 (en) | 2003-09-15 | 2007-06-14 | De Kretser David | Follistatin isoforms and uses thereof |
| AU2005266875B2 (en) | 2004-07-23 | 2012-07-26 | Acceleron Pharma Inc. | ActRII receptor polypeptides, methods and compositions |
| JP2008520207A (ja) | 2004-11-16 | 2008-06-19 | アヴィディア リサーチ インスティテュート | タンパク質骨格およびその使用 |
| US8067562B2 (en) * | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| WO2008030367A2 (en) | 2006-09-01 | 2008-03-13 | The General Hospital Corporation | Selective myostatin inhibitors |
| AU2007334333B2 (en) * | 2006-12-18 | 2013-05-30 | Acceleron Pharma Inc. | Activin-ActRII antagonists and uses for increasing red blood cell levels |
| TW201940502A (zh) | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| EP2315602A4 (en) * | 2008-06-26 | 2011-11-02 | Acceleron Pharma Inc | METHOD OF DOSING AN ACTRIIB ANTAGONIST AND MONITORING TREATED PATIENTS |
| WO2010019261A1 (en) | 2008-08-14 | 2010-02-18 | Acceleron Pharma Inc. | Use of gdf traps to increase red blood cell levels |
| US8216997B2 (en) * | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| DK2424895T3 (en) | 2009-04-27 | 2017-12-18 | Novartis Ag | Compositions and Methods for Increasing Muscle Growth |
| CN105535938B (zh) * | 2009-08-13 | 2022-04-26 | 阿塞勒隆制药公司 | Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平 |
| AU2011326586A1 (en) * | 2010-11-08 | 2013-05-30 | Acceleron Pharma, Inc. | ActRIIA binding agents and uses thereof |
-
2013
- 2013-10-23 CN CN202110622231.6A patent/CN113604550A/zh active Pending
- 2013-10-23 IL IL267663A patent/IL267663B/en unknown
- 2013-10-23 IL IL290653A patent/IL290653B2/en unknown
- 2013-10-23 WO PCT/US2013/066350 patent/WO2014066486A2/en not_active Ceased
- 2013-10-23 EP EP13848471.2A patent/EP2912462B1/en active Active
- 2013-10-23 EP EP19184182.4A patent/EP3608419B1/en active Active
- 2013-10-23 CA CA2889209A patent/CA2889209C/en active Active
- 2013-10-23 AU AU2013334659A patent/AU2013334659B2/en active Active
- 2013-10-23 US US14/438,120 patent/US20150276766A1/en not_active Abandoned
- 2013-10-23 ES ES19184182T patent/ES3031001T3/es active Active
- 2013-10-23 ES ES13848471T patent/ES2753811T3/es active Active
- 2013-10-23 JP JP2015539750A patent/JP6401171B2/ja active Active
- 2013-10-23 CN CN201380067792.8A patent/CN104968801B/zh active Active
-
2015
- 2015-04-21 IL IL238414A patent/IL238414B/en active IP Right Grant
- 2015-04-23 SA SA515360337A patent/SA515360337B1/ar unknown
-
2018
- 2018-03-09 US US15/916,634 patent/US20190049469A1/en not_active Abandoned
- 2018-07-11 JP JP2018131226A patent/JP2018184428A/ja active Pending
-
2019
- 2019-06-12 AU AU2019204098A patent/AU2019204098B2/en active Active
-
2020
- 2020-06-24 JP JP2020108569A patent/JP7146850B2/ja active Active
-
2021
- 2021-09-21 AU AU2021236465A patent/AU2021236465B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018184428A5 (cg-RX-API-DMAC7.html) | ||
| JP2016500698A5 (cg-RX-API-DMAC7.html) | ||
| JP2020183389A5 (cg-RX-API-DMAC7.html) | ||
| Hyldgaard et al. | A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality | |
| Zlatanova et al. | Iron regulator hepcidin impairs macrophage-dependent cardiac repair after injury | |
| Macrez et al. | Mechanisms of glutamate toxicity in multiple sclerosis: biomarker and therapeutic opportunities | |
| Kontovinis et al. | Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers | |
| Sanna et al. | Suicidal ideation and physical illness: does the link lie with depression? | |
| Takeuchi et al. | Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study) | |
| Tandon et al. | Unraveling links between chronic inflammation and long COVID: workshop report | |
| Iglesias‐Linares et al. | The use of gene therapy vs. corticotomy surgery in accelerating orthodontic tooth movement | |
| UA126786C2 (uk) | Fgfr/pd-1 комплексна терапія для лікування раку | |
| Gu et al. | Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors | |
| JP2018522579A5 (cg-RX-API-DMAC7.html) | ||
| Strawser et al. | Therapeutic approaches for the treatment of Friedreich’s ataxia | |
| KR20180002838A (ko) | 모발 생장을 촉진하기 위한 방법 및 조성물 | |
| Piątkiewicz et al. | The dysfunction of NK cells in patients with type 2 diabetes and colon cancer | |
| Stasyshyn et al. | Prophylaxis with anti‐inhibitor coagulant complex improves health‐related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study | |
| EP4371125A1 (en) | Multi-variate model for predicting cytokine release syndrome | |
| Ding et al. | Clinical utility and prognostic implications of the novel 4S-AF scheme to characterize and evaluate patients with atrial fibrillation: a report from ESC-EHRA EORP-AF Long-Term General Registry | |
| Chastan et al. | Cardiac conduction alterations in a French family with amyloidosis of the Finnish type with the p. Asp187Tyr mutation in the GSN gene | |
| Jiang et al. | Anti-CCL21 antibody attenuates infarct size and improves cardiac remodeling after myocardial infarction | |
| Fisser et al. | The impact of epicardial adipose tissue in patients with acute myocardial infarction | |
| Caruso et al. | Novel advances in treatment of meningiomas: prognostic and therapeutic implications | |
| Melissaropoulos et al. | Pathogenetic aspects of systemic sclerosis: a view through the prism of B cells |